Product Portfolio


Oleogel-S10 (AP101) is Amryt’s lead development candidate, a potential treatment for Epidermolysis Bullosa (“EB”), a rare and distressing genetic skin disorder affecting young children and adults for which there is currently no approved treatments available.  Oleogel-S10 is currently in a Phase 3 clinical trial and recently reported positive unblinded interim efficacy and safety analyses.  It is anticipated this study will be fully enrolled by the end of 2019. The European and US market opportunity for EB is estimated to be in excess of $1 billion.

Tubes with liquid